Hepatitis C virus therapy-related skin manifestations

Gastroenterology and Hepatology

Volumn 6, Issue 5, 2010, Pages 326-328

  Fortune, Brett E ^a   Francis, Shayla ^a   Forman, Lisa M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; ANTIHISTAMINIC AGENT; CORTICOSTEROID; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STEROID;

ALOPECIA; ARTHRALGIA; BULLOUS SKIN DISEASE; CLINICAL TRIAL; DEPRESSION; DERMATITIS; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA MULTIFORME; ERYTHRODERMA; EXFOLIATIVE DERMATITIS; FATIGUE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; INJECTION SITE REACTION; INSOMNIA; LICHEN PLANUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MEASLES LIKE RASH; MYALGIA; NAUSEA; NEUTROPENIA; NOTE; PATIENT COMPLIANCE; PRURITUS; PSORIASIS; RISK FACTOR; SIDE EFFECT; SKIN DEFECT; SKIN MANIFESTATION; SKIN NECROSIS; SWEATING; VASCULITIS; VESICULOBULLOUS ERUPTION;

EID: 77953307901     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (32)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(suppl 1):74-81.
2. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-288.
3. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684.
4. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2008;27:542-551.
5. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313. (Pubitemid 34465173)
6. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997;26:780-785. (Pubitemid 27392374)
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
8. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040-1048. (Pubitemid 44515099)
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
10. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
11. Veluru C, Atluri D, Chadalavada R, Burns E, Mullen KD. Skin rash during chronic hepatitis C therapy. Gastroenterol Hepatol. 2010;6:323-325.
12. Chung CM, Nunley JR. Overview of hepatitis C and skin. Dermatol Nurs. 2006;18:425-430.
13. Pearlman BL. Hepatitis C infection: a clinical review. South Med J. 2004;97:365-373.
14. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12:611-636.
15. Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol. 2004;150:1046-1047; author reply 1047.
16. Stafford-Fox V, Guindon KM. Cutaneous reactions associated with alpha interferon therapy. Clin J Oncol Nurs. 2000;4:164-168.
17. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005;22:519-528.
18. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237-S244.
19. Gallelli L, Ferraro M, Mauro GF, De Sarro G. Generalized exfoliative dermatitis induced by interferon alfa. Ann Pharmacother. 2004;38:2173-2174.
20. Litt JZ. Ribavirin. Drug Eruption Reference Manual. 11th ed. Abingdon, UK: Taylor and Francis Group; 2005:451.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
22. Bolognia JL, Jorizzo JL, Rapini R. Urticarias, erythemas, and purpuras. Dermatology. Spain: Mosby-Elseiver; 2008:304.
23. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005;153:1088-1090.
24. Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253-261.
25. Hardman JG, Limbird LE. Antimicrobial agents: antiviral agents. Gilbert and Goodman's The Pharmacologic Basis of Therapeutics. 10th Ed. New York, New York: McGraw-Hill; 2001:1336-1337.
26. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965.
27. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451-458.
28. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493-1499. (Pubitemid 28543497)
29. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002-1009.
30. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-714.
31. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-1358.
32. Hultgren C, Milich DR, Weiland O, Sällberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;79:2381-2391. (Pubitemid 28464295)